What the FDA labels say about taking them together
Ensitrelvir and methylergonovine
Ensitrelvir's FDA label of June 3, 2026 names methylergonovine in its drug interactions section; the methylergonovine label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues, including the central nervous system.”
Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the methylergonovine FDA label on DailyMed (effective May 1, 2026, Teva Pharmaceuticals USA, Inc.).
What does the ensitrelvir label say about methylergonovine?
Ensitrelvir label, drug interactionsDrug Class: Ergot derivatives; Drug (s) within Class: dihydroergotamine, ergotamine, methylergonovine; Effect on Drug Concentration: ↑ dihydroergotamine, ergotamine, methylergonovine; Clinical Comment: Co-administration is contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues, including the central nervous system.
Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed
What does the methylergonovine label say about ensitrelvir?
Methylergonovine's label (effective May 1, 2026) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methylergonovine Maleate), Teva Pharmaceuticals USA, Inc., effective May 1, 2026 (SPL set d8e4b8ed-3289-4611-8a61-2392a4bf6072), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ensitrelvir | Methylergonovine | |
|---|---|---|
| Labeled for | COVID-19 | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $4.50 per tablet 0.2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once